Table 2.
WHO category, molecular characteristics, and type of treatment of the study population.
| Variable | Total Cohort, n = 269 | Younger Patients (<60 y), n = 123 |
Older Patients (≥60 y), n = 146 |
|---|---|---|---|
| WHO 2016 category, n (%) | 269 | 123 (45.7) | 146 (54.3) |
| AML with genetic abnormalities | |||
| t(8;21) | 6 (2.2) | 5 (4.1) | 1 (0.7) |
| inv16 | 11 (4.1) | 6 (4.9) | 5 (3.4) |
| KMT2A rearranged | |||
| t(9;11) | 3 (1.1) | 2 (1.6) | 1 (0.7) |
| t(11;19) | 1 (0.4) | 1 (0.8) | 0 |
| t(6;9) | 2 (0.7) | 2 (1.6) | 0 |
| inv3 | 0 | 0 | 0 |
| mutated NPM1 | 68 (25.3) | 33 (26.8) | 35 (24.0) |
| AML with Myelodysplasia-related changes | 54 (20.1) | 15 (12.2) | 39 (26.7) |
| Therapy related | 27 (10.0) | 16 (13.0) | 11 (7.5) |
| AML, NOS | 95 (35.3) | 43 (35.0) | 52 (35.6) |
| Myeloid sarcoma | 2 (0.7) | 0 | 2 (1.4) |
| ELN 2017 Risk stratification, n (%) | |||
| Favorable | 57 (21.2) | 31 (25.2) | 26 (17.8) |
| Intermediate | 50 (18.6) | 29 (23.6) | 21 (14.4) |
| Adverse | 98 (36.4) | 30 (24.4) | 68 (46.6) |
| Favorable/Intermediate | 26 (9.7) | 14 (11.4) | 12 (8.2) |
| Intermediate/Adverse | 11 (4.1) | 7 (5.7) | 4 (2.7) |
| Indeterminate | 27 (10.0) | 12 (9.8) | 15 (10.3) |
| Mutated gene, n (%) | |||
| FLT3 * | 57 (21.2) | 31 (25.2) | 26 (17.8) |
| FLT3-ITD | 44 (16.4) | 25 (20.3) | 19 (13.0) |
| FLT3-TKD | 15 (5.6) | 6 (4.9) | 9 (6.2) |
| NPM1 | 76 (28.3) | 37 (30.1) | 39 (26.7) |
| DNMT3A | 67 (24.9) | 28 (22.8) | 39 (26.7) |
| RUNX1 | 25(9.3) | 4 (3.3) | 21 (14.4) |
| ASXL1 | 37 (13.8) | 10 (8.1) | 27 (18.5) |
| TP53 | 27 (10.0) | 5 (4.1) | 22 (15.1) |
| IDH1 | 28 (10.4) | 11 (8.9) | 17 (11.6) |
| IDH2 | 36 (13.4) | 16 (13.0) | 20 (13.7) |
| BCOR | 15 (5.6) | 7 (5.7) | 8 (5.5) |
| SETBP1 | 3 (1.1) | 0 | 3 (2.1) |
| ZRSR2 | 6 (2.2) | 0 | 6 (4.1) |
| WT1 | 12 (4.5) | 9 (7.3) | 3 (2.1) |
| Treatment, n (%) | |||
| Intensive chemotherapy | 179 (66.5) | 114 (92.7) | 65 (44.5) |
| Low-intensive chemotherapy (AZA/LDAC) | 38 (14.1) | 1 (0.8) | 37 (25.3) |
| Best supportive care | 32 (11.9) | 2 (1.6) | 30 (20.5) |
| Died before treatment | 9 (3.3) | 3 (2.4) | 6 (4.1) |
| Not available | 11 (4.1) | 3 (2.4) | 8 (5.5) |
| HSCT | 35 (13.0) | 31 (25.2) | 4 (2.7) |
NOS: not otherwise specified; ELN: European LeukemiaNet; AZA: azacytidine; LDAC: low-dose cytarabine; HSCT: hematopoietic stem cell transplant. * The asterisk highlights that in the indicated group, two patients (≥60 years) had concomitant FLT3-ITD and FLT3-TKD mutations. Because the FLT3-ITD allelic burden [8] was not available, patients containing both FLT3-ITD and NPM1 mutations were considered favorable|intermediate risk, whereas patients containing FLT3-ITD but no NPM1 mutation were considered intermediate|adverse risk.